Amivantamab Plus Lazertinib Clinical Efficacy
Panelists discuss how the MARIPOSA study shows more patients in the amivantamab-lazertinib arm continued treatment compared to osimertinib, and many who progressed initiated subsequent therapy, primarily with carboplatin-pemetrexed.
EP: 1.Overview of MARIPOSA Study
Now Viewing
EP: 2.Amivantamab Plus Lazertinib Clinical Efficacy
EP: 3.Safety Considerations for Frontline Amivantamab Plus Lazertinib
EP: 4.Amivantamab Plus Lazertinib Added to NCCN for Frontline NSCLC
EP: 5.Putting Amivantamab Plus Lazertinib Into Practice
EP: 6.Longer Follow-Up Data Maintain Lasting Responses With Amivantamab/ Lazertinib in EGFR-Mutant NSCLC
Recent Videos
